Express News | Zhaoke Ophthalmology: The first patient has been enrolled in the Phase III clinical trial of Cyclosporine A eye gel.

BreakingsApr 17 16:38

Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal

MT NewswiresApr 16 19:16

ZHAOKE OPHTH-B (06622.HK) has signed three distribution agreements with Interpharma to commercialize NVK002, BRIMOCHOL PF, and six glaucoma medications in Thailand.

On April 16, Gelonghui reported that ZHAOKE OPHTH-B (06622.HK) announced that the company has entered into three distribution and supply agreements with Interpharma for the commercialization in Thailand of (i) NVK002 (an innovative therapy to control myopia progression); (ii) BRIMOCHOL PF (an innovative drug for the treatment of presbyopia); and (iii) six generic drugs for glaucoma (bimatoprost, brimonidine tartrate, latanoprost, latanoprost tartrate, travoprost, and travoprost tartrate) (collectively referred to as "the products"). According to the terms of the agreement, ZHAOKE OPHTH will grant.

Gelonghui FinanceApr 16 17:09

Zhaoke Ophthalmology (06622.HK) has enrolled the first patient in the Phase II clinical trial for the treatment of presbyopia and established a distribution agreement with Lunatus regarding the drug.

ZHAOKE OPHTH-B (06622.HK) announced that the first patient was enrolled in the Phase II clinical trial of BRIMOCHOL PF on March 24, 2025. This drug is one of the group's candidate medications, intended for the treatment of presbyopia. The Phase II clinical trial is a multicenter, randomized, double-blind, crossover, and placebo-controlled study. The primary purpose of this trial is to evaluate the efficacy and safety of the eye drop for presbyopic patients in China. The trial is led by Professor Qu Jia from the Affiliated Eye Hospital of Wenzhou Medical University, involving 14 centers and enrolling a total of 119 patients. The Board of Directors also announced.

AASTOCKSApr 11 17:24

ZHAOKE OPHTH-B (06622.HK): Tenpoint has submitted a new drug application for BRIMOCHOLPF to the FDA, accelerating the global process for the treatment of presbyopia.

On April 11, Gelonghui reported that ZHAOKE OPHTH-B (06622.HK) announced the enrollment of the first patient in the Phase II clinical trial of BRIMOCHOLPF (one of the company's candidate drugs, indicated for presbyopia) on March 24, 2025. This Phase II clinical trial is a multicenter, randomized, double-blind, crossover, and placebo-controlled study. The main objective of the trial is to evaluate the efficacy and safety of BRIMOCHOLPF eye drops in Chinese patients with presbyopia. The trial is led by Professor Qu Jia from the Wenzhou Medical University Affiliated Eye Hospital and will involve 14 centers, and

Gelonghui FinanceApr 11 17:23

Zhaoke Ophthalmology Shrinks Loss in 2024

MT NewswiresMar 25 17:46